Celldex Therapeutics (CLDX) was upgraded by Barclays PLC from "underweight" to "overweight". They now have a $45.00 price target on the stock.
Celldex to Present at Upcoming Investor Conference
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Is Celldex's US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? [Yahoo! Finance]
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch [Seeking Alpha]